Pharmaceuticals-maker Sanofi-Synthelabo formally announced plans Monday to create the world’s third-largest pharmaceutical company after making a new, “friendly” bid for the Franco-German Aventis SA ...
Sanofi Synthélabo, the French pharmaceuticals group, on Monday launched a €48.5bn ($61 billion) hostile takeover bid for Aventis, its larger Franco-German rival, in a daring move to create the ...
- Focused on translational biomedical research in multiple therapeutic areas such as cancer, diabetes and inflammation - PARIS, Oct. 18 /PRNewswire/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) ...
French drug maker Sanofi-Aventis SA has agreed to buy Genzyme Corp. in a sweetened all-cash $20.1 billion deal that ends months of corporate haggling and positions Sanofi at the forefront of the ...
WALTHAM, Mass.--Avila Therapeutics, Inc. announced today that it has signed a worldwide strategic alliance with sanofi-aventis (EURONEXT: SAN and NYSE: SNY) to discover targeted covalent drugs for the ...
Where there are threats of serious or irreversible damage, lack of full scientific certainty shall not be used as a reason for postponing cost-effective measures to prevent environmental degradation. ...
Sanofi-aventis will provide $160 million annually until the end of 2017. Sanofi-aventis is extending its mAb partnership with Regeneron Pharmaceuticals by five years and will pay 60% more in annual ...
We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results